Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited (TSE: 4568) is one of Japan’s largest and fastest-growing research-based biopharmaceutical corporations and the global pioneer in deruxtecan (DXd) antibody-drug conjugates (ADCs). In FY2025 (fiscal year ended March 31, 2026), consolidated revenue increased 12.6% year-on-year to JPY 2,123.0 billion (USD 13.40 billion), core operating profit rose 15.1% to JPY 360.0 billion, and net income attributable to owners reached JPY 259.9 billion (USD 1.64 billion), supported by a global workforce of 18,726 employees and a market capitalization of JPY 5,053.5 billion (USD 31.89 billion).

Industry Position

Over the past five years, Daiichi Sankyo has executed one of the most successful structural transformations in the global pharmaceutical industry, pivoting from a domestic primary-care and cardiovascular drugmaker into a top-tier global oncology leader. Between FY2021 and FY2025, consolidated revenue more than doubled from JPY 1,044.9 billion to JPY 2,123.0 billion, while overseas sales surged from 46.6% to 72.7% of total revenue. In the global ADC market, Daiichi Sankyo commands the leading clinical and commercial position through Enhertu (trastuzumab deruxtecan), which achieved JPY 698.4 billion in group-booked revenue in FY2025 (including JPY 86.0 billion in sales milestones after combined global alliance sales surpassed USD 5.0 billion) and is projected to reach JPY 861.3 billion in FY2026. Alongside its second commercialized DXd ADC, Datroway (datopotamab deruxtecan), which gained U.S. FDA approval in May 2026 for unresectable or metastatic triple-negative breast cancer following earlier approvals in HR-positive, HER2-negative breast cancer, Daiichi Sankyo ranks among the top two Japanese pharmaceutical companies by revenue and equity market valuation alongside Takeda Pharmaceutical and Chugai Pharmaceutical.

Competitive Advantages

Daiichi Sankyo’s primary competitive moat rests on its proprietary DXd ADC technology platform, engineered entirely in its Japanese laboratories. The platform combines a potent topoisomerase I inhibitor payload (exatecan derivative, DXd) with a tumor-selective cleavable tetrapeptide-based linker, a high drug-to-antibody ratio (DAR of approximately 8 for Enhertu and 4 for Datroway), and a strong bystander antitumor effect that destroys neighboring cancer cells regardless of target expression heterogeneity. This scientific edge enabled Enhertu to redefine treatment paradigms across HER2-positive, HER2-low, and HER2-ultralow breast cancer, gastric cancer, and non-small cell lung cancer, maintaining the number-one new-patient market share across the United States, Europe, and Japan. Second, Daiichi Sankyo has amplified its commercial reach and de-risked clinical development through landmark global co-development and co-commercialization alliances: two global partnerships with AstraZeneca (for Enhertu in 2019 and Datroway in 2020) and a multi-asset alliance with Merck & Co. (signed in October 2023 for up to USD 22.0 billion covering three DXd ADCs: patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan). Third, its domestic pharmaceutical franchise in Japan (JPY 515.0 billion in FY2025) and European cardiovascular franchise (JPY 268.0 billion) provide resilient cash flows anchored by direct oral anticoagulant Lixiana (edoxaban), neuropathic pain therapy Tarlige, and lipid-lowering therapies Nilemdo and Nustendi, sustaining an industry-leading consolidated gross margin of 79.2% and return on equity of 15.8%.

Strategic Expansion

In May 2026, Daiichi Sankyo launched its sixth 5-Year Business Plan (FY2026–FY2030), targeting consolidated revenue exceeding JPY 3.0 trillion, core operating profit before R&D expenses above JPY 1.2 trillion, and basic earnings per share above JPY 260 by FY2030. Momentum in the first half of FY2026 (six months ended September 30, 2026) confirmed this trajectory, with 1H revenue jumping 19.7% year-on-year to JPY 1,167.2 billion, Oncology Business Unit revenue surging 54.8% to JPY 422.6 billion, and core operating profit climbing 46.9% to JPY 221.3 billion. To sharpen its capital allocation as a pure-play innovative biopharmaceutical leader, Daiichi Sankyo divested its domestic generics subsidiary Daiichi Sankyo Espha, excluded two chemical/contract manufacturing subsidiaries from consolidation, and resolved on March 31, 2026 to transfer 100% of its consumer OTC subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (JPY 90.7 billion in FY2025 revenue), to Suntory Holdings. Simultaneously, the company is expanding global ADC biologics and linker-payload manufacturing capacity across Japan, Germany, the United States, and China while advancing next-generation modalities including second-generation ADCs, bispecific antibodies, and mRNA vaccines.

Risks & Outlook

Despite robust top-line expansion, Daiichi Sankyo faces notable operational and clinical concentration risks. First, under its alliance agreements, Daiichi Sankyo books global product sales outside Japan in major territories and pays AstraZeneca a 50% share of gross profit, causing selling, general, and administrative expenses to surge 18.6% to JPY 859.6 billion (40.5% of revenue) in FY2025. Second, supply-chain and capacity adjustments can trigger substantial non-core charges, as evidenced in FY2025 when JPY 133.2 billion in fourth-quarter temporary expenses—including JPY 88.3 billion in contract manufacturing organization (CMO) compensation fees and JPY 19.3 billion from canceling Odawara site investments—reduced GAAP operating profit by 31.0% to JPY 229.1 billion. Third, the US injectable iron franchise at American Regent declined 16.1% in FY2025 to JPY 182.4 billion and another 19.5% in 1H FY2026 due to competitive pressures on Injectafer and Venofer, while Lixiana faces approaching patent expirations later in the decade. Nevertheless, with full-year FY2026 revenue guided at JPY 2,280.0 billion (+7.4%) and operating profit projected to rebound 37.5% to JPY 315.0 billion alongside an annual dividend increase to JPY 100 per share, Daiichi Sankyo earns a VerityRank Score of 88/100.